Premium
Biomarker changes associated with clinical symptoms in MELAS patient
Author(s) -
Matsui Misa,
Yamadera Misaki,
Saito Toshio,
Fujimura Harutoshi,
Sakoda Saburo,
Koga Yasutoshi
Publication year - 2019
Publication title -
neurology and clinical neuroscience
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.125
0ISSN - 2049-4173
DOI - 10.1111/ncn3.12325
Subject(s) - medicine , biomarker , disease , stage (stratigraphy) , mitochondrial disease , mitochondrial dna , oncology , pathology , biochemistry , chemistry , paleontology , gene , biology
FGF21 and GDF15 are known as useful biomarkers for diagnosis of mitochondrial disorders, though their efficacy for evaluating disease severity is not well established. We determined their levels in a patient with a mitochondrial disorder and report our findings. Both biomarkers were elevated at the initial disease stage and then greatly increased with progression. Furthermore, those levels decreased along with improved clinical symptoms in response to pyruvate therapy.